Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 4, 2003, Pages 1213-1219

  Fukuoka, Takashi ^a,d   Johnston, Douglas A ^a   Winslow, Carol A ^b   De Groot, Marcel J ^b   Burt, Catherine ^b   Hitchcock, Christopher A ^b   Filler, Scott G ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; FLUCONAZOLE; MICONAZOLE; VORICONAZOLE;

ANIMAL CELL; ANTIFUNGAL ACTIVITY; ARTICLE; BINDING SITE; CANDIDA KRUSEI; CANDIDIASIS; DRUG ACCUMULATION; DRUG EFFECT; ENZYME INHIBITION; FUNGUS ISOLATION; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; HYDROPHOBICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANTIFUNGAL AGENTS; CANDIDA; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, FUNGAL; ENZYME INHIBITORS; FLUCONAZOLE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; OXIDOREDUCTASES; PROTEIN STRUCTURE, SECONDARY; PYRIMIDINES; TRIAZOLES;

EID: 0037378067     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.4.1213-1219.2003     Document Type: Article

References (29)

1. Abbas, J., G. P. Bodey, H. A. Hanna, M. Mardani, E. Girgawy, D. Abi-Said, E. Whimbey, R. Hachem, and I. Raad. 2000. Candida krusei fungemia. An escalating serious infection in immunocompromised patients. Arch. Intern. Med. 160:2659-2664.
2. Abola, E. E., J. L. Sussman, J. Prilusky, and N. O. Manning. 1997. Protein Data Bank archives of three-dimensional macromolecular structures. Methods Enzymol. 277:556-571.
3. Agatep, R., R. Kirkpatrick, D. Parchaliuk, R. Woods, and R. Gietz. 1998. Transformation of Saccharomyces cerevisiae by the lithium acetate/single-stranded carrier DNA/polyethylen glycol (LiAc/ss-DNA/PEG) protocol. Tech. Tips Online [Online.] http://tto.trends.com.
4. Burgener-Kairuz, P., J. P. Zuber, P. Jaunin, T. G. Buchman, J. Bille, and M. Rossier. 1994. Rapid detection and identification of Candida albicans and Torulopsis (Candida) glabrata in clinical specimens by species-specific nested PCR amplification of a cytochrome P-450 lanosterol-α-demethylase (L1A1) gene fragment. J. Clin. Microbiol. 32:1902-1907.
5. Espinel-Ingroff, A., K. Boyle, and D. J. Sheehan. 2001. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 150:101-115.
6. Goldman, M., J. C. Pottage, Jr., and D. C. Weaver. 1993. Candida krusei fungemia. Report of 4 cases and review of the literature. Medicine (Baltimore) 72:143-150.
7. Iwen, P. C., D. M. Kelly, E. C. Reed, and S. H. Hinrichs. 1995. Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole. Clin. Infect. Dis. 20:342-347.
8. Ji, H., W. Zhang, Y. Zhou, M. Zhang, J. Zhu, Y. Song, and J. Lu. 2000. A three-dimensional model of lanosterol 14alpha-demethylase of Candida albicans and its interaction with azole antifungals. J. Med. Chem. 43:2493-2505.
9. Katiyar, S. K., and T. D. Edlind. 2001. Identification and expression of multidrug resistance-related ABC transporter genes in Candida krusei. Med. Mycol. 39:109-116.
10. Lamb, D. C., D. E. Kelly, T. C. White, and S. L. Kelly. 2000. The R467K amino acid substitution in Candida albicans sterol 14α-demethylase causes drug resistance through reduced affinity. Antimicrob. Agents Chemother. 44:63-67.
11. Laskowski, R. A., M. W. McArthur, D. S. Moss, and J. M. Thornton. 1993. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26:283-291.
12. Loffler, J., S. L. Kelly, H. Hebart, U. Schumacher, C. Lass-Florl, and H. Einsele. 1997. Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol. Lett. 151:263-268.
13. Marichal, P., L. Koymans, S. Willemsens, D. Bellens, P. Verhasselt, W. Luyten, M. Borgers, F. C. Ramaekers, F. C. Odds, and H. V. Bossche. 1999. Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 145:2701-2713.
14. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard. NCCLS document M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
15. Nguyen, M. H., and C. Y. Yu. 1998. Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole. J. Antimicrob. Chemother. 42:253-256.
16. Ochman, H., A. S. Gerber, and D. L. Hartl. 1988. Genetic applications of an inverse polymerase chain reaction. Genetics 120:621-623.
17. Orozco, A. S., L. M. Higginbotham, C. A. Hitchcock, T. Parkinson, D. Falconer, A. S. Ibrahim, M. A. Ghannoum, and S. G. Filler. 1998. Mechanism of fluconazole resistance in Candida krusei. Antimicrob. Agents Chemother. 42:2645-2649.
18. Ser codon in some Candida species as inferred from a molecular phylogeny. Genetics 141:903-907.
19. Podust, L. M., T. L. Poulos, and M. R. Waterman. 2001. Crystal structure of cytochrome P450 14alpha-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proc. Natl. Acad. Sci. USA 98:3068-3073.
20. Podust, L. M., J. Stojan, T. L. Poulos, and M. R. Waterman. 2001. Substrate recognition sites in 14alpha-sterol demethylase from comparative analysis of amino acid sequences and X-ray structure of Mycobacterium tuberculosis CYP51. J. Inorg. Biochem. 87:227-235.
21. Sali, A., and T. L. Blundell. 1993. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234:779-815.
22. Sanglard, D., F. Ischer, L. Koymans, and J. Bille. 1998. Amino acid substitutions in the cytochrome P-450 lanosterol 14α-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob. Agents Chemother. 42:241-253.
23. Sorkhoh, N. A., M. A. Ghannoum, A. S. Ibrahim, R. J. Stretton, and S. S. Radwan. 1991. Growth of Candida albicans in the presence of hydrocarbons: a correlation between sterol concentration and hydrocarbon uptake. Appl. Microbiol. Biotechnol. 34:509-512.
24. Sussman, J. L., D. Lin, J. Jiang, N. O. Manning, J. Prilusky, O. Ritter, and E. E. Abola. 1998. Protein Data Bank (PDB): database of three-dimensional structural information of biological macromolecules. Acta Crystallogr. D Biol. Crystallogr. 54:1078-1084.
25. Talele, T. T., S. S. Kulkarni, and V. M. Kulkarni. 1999. Development of pharmacophore alignment models as input for comparative molecular field analysis of a diverse set of azole antifungal agents. J. Chem. Infect. Comput. Sci. 39:958-966.
26. Talele, T. T., and V. M. Kulkarni. 1999. Three-dimensional quantitative structure-activity relationship (QSAR) and receptor mapping of cytochrome P-450(14 alpha DM) inhibiting azole antifungal agents. J. Chem. Infect. Comput. Sci. 39:204-210.
27. Talibi, D., and M. Raymond. 1999. Isolation of a putative Candida albicans transcriptional regulator involved in pleiotropic drug resistance by functional complementation of a pdr1 pdr3 mutation in Saccharomyces cerevisiae. J. Bacteriol. 181:231-240.
28. Triglia, T., M. G. Peterson, and D. J. Kemp. 1988. A procedure for in vitro amplification of DNA segments that lie outside the boundaries of known sequences. Nucleic Acids Res. 16:8186.
29. Venkateswarlu, K., D. W. Denning, N. J. Manning, and S. L. Kelly. 1996. Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance. Antimicrob. Agents Chemother. 40:2443-2446.